Physician profile
Michael T Morris
NPI 1245409101
$4,801.04
in general payments reported to CMS, 2019-2025
35 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $401 · 2021: $727 · 2022: $1,093 · 2023: $637 · 2024: $661 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,035.80 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $650.64 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $466.77 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.81 | 2021-2025 | Jardiance |
| Pfizer INC. | $349.59 | 2021-2025 | |
| Boston Scientific Corporation | $192.32 | 2024-2025 | Watchman Flx, Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $167.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.40 | 2020-2024 | Farxiga |
| Astellas Pharma US INC | $133.95 | 2021-2022 | |
| Baxter Healthcare | $126.45 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $126.20 | 2020-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $124.98 | 2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $112.33 | 2019-2021 | |
| Abbott Laboratories | $99.85 | 2021-2024 | Mitraclip |
| Arbor Pharmaceuticals, INC. | $83.78 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $69.86 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $65.20 | 2024-2025 | Amvuttra |
| Edwards Lifesciences Corporation | $57.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $56.00 | 2020-2021 | |
| Allergan, INC. | $50.01 | 2019-2020 | |
| Vital Connect, INC | $46.87 | 2024-2025 | Vitalpatch Rtm |
| Kowa Pharmaceuticals America, INC. | $34.48 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.84 | 2019 | |
| Bardy Diagnostics, INC. | $28.94 | 2021-2022 | |
| Amarin Pharma, INC. | $24.89 | 2020 | |
| Chiesi USA, INC. | $20.00 | 2021 | |
| Angiodynamics, INC. | $18.87 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $18.69 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.41 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $17.00 | 2022 | |
| Medicure Pharma INC. | $14.00 | 2022 | |
| Abbvie INC. | $11.65 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.